/Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)

Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)

$30.00

ORIGINAL RESEARCH

Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)

By Prakash S. Masand, MD, James Eudicone, MS, Andrei Pikalov, MD, PhD, Robert D. McQuade, PhD, Ronald N. Marcus, MD, Estelle Vester-Blokland, MD and Berit X. Carlson, PhD

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Description

ORIGINAL RESEARCH

Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)

By Prakash S. Masand, MD, James Eudicone, MS, Andrei Pikalov, MD, PhD, Robert D. McQuade, PhD, Ronald N. Marcus, MD, Estelle Vester-Blokland, MD and Berit X. Carlson, PhD

PB-41-2-04-Masand